Nutex Health Inc. (NUTX) SEC Filings

Nutex Health Inc. (NUTX) reported that it recently detected unauthorized activity involving data stored on its computer network. The company engaged an independent third-party cybersecurity response team and forensic experts, activated a cybersecurity response plan, implemented containment measures, and notified law enforcement.

Preliminary findings indicate that certain information on Nutex Health’s servers was accessed and exfiltrated by an unauthorized third party, including some potentially private or confidential data. As of August 24, 2026, Nutex Health states it has not identified any material impact on business operations or financial reporting systems and does not believe the incident has had, or is reasonably likely to have, a material impact on its business strategy, operations, financial condition, or results of operations. The company is continuing its investigation, assessing whether patient, employee, provider, confidential business, financial information, or intellectual property was involved, and is evaluating regulatory and legal notification obligations, including notifications to impacted patients if required.

Nutex Health Inc. reports that on August 11, 2026, the U.S. Court of Appeals for the Fifth Circuit, sitting en banc, issued a decision in Texas Medical Association v. HHS affecting how insurers calculate the Qualifying Payment Amount (QPA) under the No Surprises Act. The court held that insurers may not include so‑called “ghost rates” in QPA calculations and must include bonus and incentive payments, vacating key portions of a July 2021 interim final rule issued by federal Departments. Nutex, as a healthcare provider subject to No Surprises Act reimbursement and arbitration processes linked to the QPA, highlights that the court described prior inclusion of ghost rates as artificially suppressing QPAs and noted that arbitration awards exceeded the QPA in 85% of disputes. The decision directs federal Departments to create new rules consistent with the statute while allowing existing QPAs to be used in the interim through enforcement discretion.

Nutex Health Inc. reported strong results for the three and six months ended June 30, 2026. For the quarter, net income attributable to Nutex Health rose to $65.8 million, or diluted EPS of $9.38, compared with a loss of $17.7 million, or $(2.95) per share, a year earlier. Quarterly EBITDA was $94.1 million and Adjusted EBITDA $90.0 million. For the first half of 2026, net income attributable to Nutex Health was $112.6 million with diluted EPS of $15.87, and Adjusted EBITDA was $147.5 million. Total revenue was $210,752 (in thousands) for the quarter and $427,237 (in thousands) for the first half, compared with $243,985 and $455,774 (in thousands) in 2025.

Hospital Division volumes increased, with 49,962 total visits in Q2 2026, up 9.6% year over year, and 99,704 visits for the first half, up 6.2%. Net cash provided by operating activities was $34.2 million in Q2 and $109.7 million for the first half, up from $27.3 million and $78.2 million in the prior-year periods. As of June 30, 2026, cash and cash equivalents were $205,208 (in thousands), long-term debt, net, was $31.1 million, and total equity was $507,312 (in thousands).

Nutex Health Inc. reported Q2 and first-half 2026 results showing a sharp swing to profitability. Net income attributable to Nutex Health was 65,842 (thousand) for the quarter and 112,649 (thousand) for the first six months, compared with a loss of 17,697 (thousand) and income of 3,520 (thousand) a year earlier. The improvement reflects much lower stock-based compensation and a 52,319 (thousand) reduction in contract services expense from amended arbitration cost estimates related to HaloMD and lower federal IDR fees, which increased net income attributable to Nutex by 25.0 million.

Total revenue declined to 210,752 (thousand) for Q2 and 427,237 (thousand) year‑to‑date from 243,985 (thousand) and 455,774 (thousand) in 2025, driven mainly by lower hospital division revenue, while gross profit remained strong. Cash and cash equivalents rose to 205,208 (thousand), supported by 109,718 (thousand) of operating cash flow, even as the company used 50,688 (thousand) for stock repurchases and share retirements and carried 39,899 (thousand) of debt and 49,668 (thousand) of accrued arbitration expenses. Operations remain closely tied to the evolving No Surprises Act independent dispute resolution framework, with complex reimbursement dynamics and ongoing regulatory and legal developments.

Nutex Health Inc. director Frank E. Jaumot reported acquiring 603 shares of Common Stock on July 31, 2026 through the exercise or conversion of a derivative security. A related footnote explains that restricted stock units convert into common stock on a one-for-one basis. After this transaction, he directly owns 753 shares.

Nutex Health Inc. director Cheryl Yvonne Grenas reported the exercise and conversion of restricted stock units into 603 shares of common stock on July 31, 2026. The units convert into common stock on a one-for-one basis and were recorded at $0.0000 per share, bringing her direct holdings to 670 shares after the transaction.

Nutex Health Inc. director Scott J. Saunders acquired 603 shares of common stock on 2026-07-31 through the conversion of restricted stock units, which convert into common stock on a one-for-one basis. The shares were acquired at $0.0000 per share and are held directly, totaling 603 shares.

Nutex Health director Michael Lee Reed reported the conversion of restricted stock units into 603 shares of Common Stock on July 31, 2026, at a stated price of $0.0000 per share. The shares are held indirectly through the Michael L Reed Trust IRA (MLRTIRA), bringing his reported indirect holdings to 670 shares. The transaction was not reported as made under a Rule 10b5-1 trading plan.

Nutex Health Inc. entered into a First Amendment to its Payment Dispute Resolution Services Agreement with HaloMD, L.L.C., effective June 30, 2026. The amendment shifts fees to a pay-on-collected basis retroactive to the original May 1, 2024 agreement, adjusts the service fee structure for federal and state net settlement amounts obtained on or after July 1, 2026, and allows HaloMD access to remittance data to confirm payment of awarded claims.

The company also gains the right to handle dispute resolution services in-house or through another vendor for certain future hospital facilities, and the agreement’s initial term is extended through December 31, 2029, with automatic one-year renewals. Separately, CMS and other federal agencies cut the Federal IDR non-refundable administrative fee from $115 to $15 per party per dispute, effective June 11, 2026. Nutex Health expects these changes to reduce overall arbitration-related costs.